Lizhu Group (Ningxia) Expands Enzymophenolic Acid Production Capacity to 800 Tons per Year

(Source: Jinghua Da Butong)

Recently, the public announcement of the enzyme phenolic acid technology renovation project at Lizhu Group (Ningxia) Pharmaceutical Co., Ltd. has been posted on relevant websites.

Project Overview

Project Name: Enzyme Phenolic Acid Technology Renovation Project at Lizhu Group (Ningxia) Pharmaceutical Co., Ltd.

Construction Unit: Lizhu Group (Ningxia) Pharmaceutical Co., Ltd.

Location: Pingluo Industrial Park, Shizuishan City, Ningxia

Nature of Construction: Technology renovation

Total Investment: 30 million yuan

Construction Content: Upgrading existing fermentation strains, improving fermentation raw material ratios, and adding supporting facilities such as seed tanks, fermentation tanks, filters, and transfer tanks in the current mycophenolic acid fermentation and refining workshops. Some equipment like transfer tanks will be replaced. Utility, auxiliary, and environmental protection projects will rely on existing infrastructure.

Scale of Construction: Technological renovation of existing production lines, increasing capacity from 250 tons/year to 800 tons/year.

In addition, according to previous public information, the recent public announcement of the Jiaozuo Health Yuan Biotech’s 300-ton annual mycophenolic acid project has been posted on relevant websites.

Lizhu Group’s mycophenolic acid is produced through fermentation - extraction - purification processes, with FDA approval and GMP certification. The product quality is stable and exported to over 20 countries including the United States, Europe, and Japan. It is one of the company’s core specialty raw materials.

Mycophenolic acid is a key raw material for immunosuppressants. It is not directly formulated into drugs but is used to produce mycophenolate mofetil via esterification and salts like mycophenolate sodium. These are further processed into capsules, tablets, enteric-coated tablets, and injections. It is mainly used for post-organ transplant rejection prevention and autoimmune disease treatment, making it a high-demand raw material in the transplant field.

Lizhu Group (Ningxia) Pharmaceutical Co., Ltd. is a biopharmaceutical raw material production base invested and built by Lizhu Group in Pingluo Industrial Park, Ningxia. Established in 2011, the company focuses on R&D, production, and sales of high-value-added specialty raw materials. With biotechnological fermentation as its core, it owns multiple production lines including L-phenylalanine, mevastatin, lovastatin, mycophenolic acid, and doramectin.